Guadecitabine (SGI-110) is a next generation hypomethylating agent (HMA) designed as a dinucleotide of decitabine and deoxyguanosine that is resistant to deamination by cytidine deaminase CDA).
This results in a prolonged in vivo exposure to decitabine following small volume subcutaneous (SC) administration of guadecitabine.
Safety and clinical activity in resistant MDS and AML have been shown in a Phase 1 trial (Issa et al, Lancet Oncology, 2015).
View further details below
2016 ESH-MDS: Results of a P2 study of SGI-110 in pts with r/r intermediate or high risk MDS or CMML